Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy gleason score in clinically localized prostate cancer

Prostate

Volumn 56, Issue 1, 2003, Pages 23-29

  Horiguchi, Akio ^a   Nakashima, Jun ^a   Horiguchi, Yutaka ^a   Nakagawa, Ken ^a   Oya, Mototsugu ^a   Ohigashi, Takashi ^a   Marumo, Ken ^a   Murai, Masaru ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Pathological stage; PSA based parameters; Radical prostatectomy

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE SCINTISCANNING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; PELVIS LYMPHADENECTOMY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; ROC CURVE; SCORING SYSTEM; SEMINAL VESICLE; SURGICAL APPROACH; TREATMENT INDICATION;

AGED; BIOPSY; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECTUM;

EID: 0037566884     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10239     Document Type: Article

References (25)

1. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-534.
2. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-114.
3. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-1451.
4. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-848.
5. Benoit RM, Naslund MJ, Cohen JK. Complications after radical retropubic prostatectomy in the medicare population. Urology 2000;56:116-120.
6. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001;165:1562-1568.
7. Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, Montie JE, Pearson JD, Slezak JM, Zincke H. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000;164:1591-1595.
8. Perrotti M, Pantuck A, Rabbani F, Israeli RS, Weiss RE. Review of staging modalities in clinically localized prostate cancer. Urology 1999;54:208-214.
9. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery - what we have learned and where we are going. J Urol 1999;162:293-306.
10. Djavan B, Remzi M, Zlotta A, Ravery V, Hammerer P, Reissigl A, Dobronski P, Kaisary A, Marberger M. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: Results of the prospective multicenter European trial. Urology 2002;60:4.
11. Saika T, Tsushima T, Nasu Y, Kusaka N, Miyaji Y, Takamoto H, Takeda K, Uno S, Kumon H. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. Cancer 2002;94:1685-1691.
12. Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ, Brawer MK, Schwartz MK, Vessella RL, Loughlin KR, Johnston DA, Babaian RJ. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002;167:2017-2023, discussion 2023-2014.
13. Sokoll L, Mangold L, Partin A, Epstein J, Bruzek D, Dunn W, Mohr P, Wallerson G, Chan D. Complexed prostate-specific antigen as a staging tool for prostate cancer: A prospective study in 420 men. Urology 2002;60:18.
14. Tombal B, Querton M, de Nayer P, Sauvage P, Cosyns JP, Feyaerts A, Opsomer R, Wese FX, Van Cangh PJ. Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy. Urology 2002;59:256-260.
15. Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, Kattan MW, Huland H. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol 2002;167:1306-1309.
16. Morote J, Encabo G, de Torres IM. Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer. Eur Urol 2000;38:225-229.
17. Melchior SW, Noteboom J, Gillitzer R, Lange PH, Blumenstein BA, Vessella RL. The percentage of free prostate-specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy. BJU Int 2001;88:221-225.
18. Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 1998;159:1238-1242.
19. Hara I, Miyake H, Hara S, Yamanaka N, Ono Y, Eto H, Takechi Y, Arakawa S, Kamidono S. Value of the serum prostate-specific antigen-alpha 1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer. BJU Int 2001;88:53-57.
20. Kurita Y, Suzuki A, Masuda H, Ushiyama T, Suzuki K, Fujita K. Transition zone volume-adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels. Eur Urol 1998;33:32-38.
21. Furuya Y, Ohta S, Sato N, Kotake T, Sugano I, Nagao K, Masai M. Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels. Anticancer Res 2001;21:1317-1320.
22. Zlotta AR, Djavan B, Petein M, Susani M, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng/ml. J Urol 1998;160:2089-2095.
23. Bartolozzi C, Crocetti L, Menchi I, Ortori S, Lencioni R. Endorectal magnetic resonance imaging in local staging of prostate carcinoma. Abdom Imaging 2001;26:111-122.
24. Cornud F, Flam T, Chauveinc L, Hamida K, Chretien Y, Vieillefond A, Helenon O, Moreau JF. Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology 2002;224:203-210.
25. Ikonen S, Karkkainen P, Kivisaari L, Salo JO, Taari K, Vehmas T, Tervahartiala P, Rannikko S. Magnetic resonance imaging of prostatic cancer: Does detection vary between high and low gleason score tumors? Prostate 2000;43:43-48.